Patent classifications
C08B37/0084
VARIABLE-SIZE HYDROPHOBICALLY-MODIFIED POLYMERS
In various aspects, the invention provides compositions of variable-length hydrophobically-modified polymers. These variable-length hydrophobes decorated along the hydrophilic polymer backbone provide advanced properties and allow for precise control over the behavior of the resulting amphiphilic polymer, including in aqueous solution. Such control allows for enhanced functionality of the amphiphilic polymer relative to standard single-length hydrophobe grafting designs, including for hemostasis.
HYDROPHOBICALLY MODIFIED CHITOSAN COMPOSITIONS
Disclosed herein is a polymer composition comprising an effective amount of a hydrophobically-modified polymer having functional groups along the backbone occupied by a fatty anhydride moiety. The polymer composition has a potent hemostatic action by gelling blood upon contact, and is suitable for treating internal and external bleeds. As disclosed herein, the modified polymer can be generated without the use of toxic reagents that would require removal from the product. Further, compositions are shelf stable even in a flowable form. That is, the hydrophobic grafts are not lost under product storage conditions (e.g., room temperature storage).
Catechol group modified biomacromolecular scaffold material and preparation method thereof
The invention discloses a preparation method of a catechol group modified biomacromolecular scaffold material, comprising: grafting a catechol-containing compound by amidation to obtain modified biomacromolecules; then, allowing dopamine to perform oxidized self-polymerization in a weakly alkaline buffer solution to form polydopamine (PDA) particles with a uniform particle size; next, forming a scaffold which has three cross-linking structures, namely modified biomacromolecules, modified biomacromolecules/PDA, and biomacromolecules/PDA, through interaction between catechol groups, interaction between catechol groups and PDA particles, and interaction between macromolecules and PDA particles in the modified macromolecules respectively; and cross-linking the scaffold with calcium ions, adipic dihydrazide or genipin to further adjust the degree of cross-linking and porosity of the scaffold. The prepared scaffold material has excellent biocompatibility and biodegradability, can promote cell adhesion, and has a wide application prospect in the field of tissue repair and regeneration.
Water-soluble and/or water-swellable hybrid polymer
A water-soluble and/or water-swellable hybrid polymer comprising: (i) from 5 wt.-% to 95 wt.-% water-soluble and/or water-swellable polysaccharide polymer; (ii) from 5 wt.-% to 95 wt.-% synthetic polymer comprising: (a) from 40 mol-% to 99 mol-% of repeating units according to Formula (1) ##STR00001## (b) from 0.01 mol-% to 5 mol-% crosslinking or branching units, wherein the crosslinking or branching units result from the incorporation of a monomer comprising at least two olefinically unsaturated double bonds; (c) from 0.99 mol-% to 59.99 mol-% of repeating neutral structural units;
wherein components (i) and (ii) are polymerized by radical precipitation polymerization in a polar solvent.
Composition of mannuronic diacid
The present invention relates to a mannuronic diacid oligosaccharide composition, comprising a mannuronic diacid of Formula (III) or a pharmaceutically acceptable salt thereof, wherein n is an integer from 1 to 9, m is 0, 1 or 2, and m′ is 0 or 1, and wherein the total weight of mannuronic diacids wherein n=1-5 is 80-95% of the total weight of the composition, and the ratio of the total weight of mannuronic diacids wherein n=1-3 to the total weight of mannuronic diacids wherein n=4-7 is between 1.0 and 3.5. ##STR00001##
BIOORTHOGONAL COMPOSITIONS
The present disclosure provides bioorthogonal compositions for delivering agents in a subject. The disclosure also provides methods of producing the compositions, as well as methods of using the same.
Hydrophobically modified chitosan compositions
Disclosed herein is a polymer composition comprising an effective amount of a hydrophobically-modified polymer having functional groups along the backbone occupied by a fatty anhydride moiety. The polymer composition has a potent hemostatic action by gelling blood upon contact, and is suitable for treating internal and external bleeds. As disclosed herein, the modified polymer can be generated without the use of toxic reagents that would require removal from the product. Further, compositions are shelf stable even in a flowable form. That is, the hydrophobic grafts are not lost under product storage conditions (e.g., room temperature storage).
HYDROGEL COMPOSITION FOR A SEMI-RIGID ACOUSTIC COUPLING MEDIUM IN ULTRASOUND IMAGING
Disclosed are compositions and articles for a semi-rigid hydrogel material that provides an acoustic coupling medium for ultrasound diagnostic and treatment techniques. In one aspect, a hydrogel material for an acoustic coupling medium includes a sodium alginate block copolymer, a dimethylacrylamide monomer, and water. In some implementations, the sodium alginate block copolymer is present in an amount of about 0.5 wt % to about 25 wt %, the dimethylacrylamide monomer is present in an amount of about 1 wt % to about 40 wt %, and the water is present in an amount of at least about 50 wt % of the total weight of the hydrogel composition.
Modified alginates for anti-fibrotic materials and applications
Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
Methods and Compositions for Maintaining the Conformation and Structural Integrity of Biomolecules
A liquid ink composition includes a liquid phase and particles suspended in the liquid phase, the particles containing a target pharmaceutical or biological agent. The biological activity of the target pharmaceutical or biological agent is preserved upon suspension of the particles in the liquid phase. The liquid phase is capable of solidifying via a solidification process.